AlloVir, a Phase 2 biotech developing allogeneic T cell therapies for viral diseases, raised $276 million by offering 16.3 million shares at $17, the midpoint of the range of $16 to $18. The company offered 1.5 million more shares than anticipated. At pricing, the company commands a fully diluted market value of $1.1 billion.
AlloVir plans to list on the Nasdaq under the symbol ALVR. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler acted as lead managers on the deal.
Viral disease biotech AlloVir prices upsized IPO at $17 midpoint
July 30, 2020

